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The adapter SLP-76 is essential for thymocyte development. SLP-
76/ mice were reconstituted with SLP-76 deletion mutant trans-
genes to examine the role of SLP-76 domains in T cell development
and function. The N-terminal domain deletion mutant completely
failed to restore thymocyte development. Mice reconstituted with
Gads-binding site and SH2 domain deletion mutants had decreased
thymic cellularity, impaired transition from double to single posi-
tive thymocytes, and decreased numbers of mature T cells in the
spleen. Calcium mobilization and extracellular signal-regulated
protein kinase activation were decreased in the Gads-binding site
mutant but almost normal in the SH2 domain mutant. T cells from
both mutants failed to proliferate following T cell antigen receptor
ligation. Nevertheless, both mutants mounted partial cutaneous
hypersensitivity responses and normal T cell dependent IgG1
antibody responses. These results indicate differential roles for
SLP-76 domains in T cell development, proliferation and effector
functions.
SLP-76 is an adapter protein predominantly expressed inhematopoietic cells (1). SLP-76 has three distinct domains:
an NH2-terminal domain (amino acids 1–155), a central proline
rich domain (amino acids 156–421) that includes a Gads binding
site (amino acids 224–244), and a C-terminal SH2 domain
(amino acids 422–533). Phosphorylated tyrosine residues in the
NH2-terminal domain bind SH2-domain containing proteins
that include Vav, Nck, and the Tec kinase Itk (2–4). The SLP-76
central proline rich domain associates with SH3-containing
proteins that include Gads and PLC-1. Upon T cell antigen
receptor (TCR) stimulation, Gads recruits SLP-76 to linker of
activated T cells (LAT). This translocates SLP-76 to glycolipid
enriched microdomains (GEM) (5, 6). LAT through Grb2
interacts with Sos, a guanine nucleotide exchange factor for Ras
GTPases, and may link SLP-76 to the Rasmitogen-activated
protein kinase (MAPK)extracellular signal-regulated protein
kinase (ERK) pathway. Finally, the SLP-76 SH2-domain inter-
acts with phosphoproteins such as FybSLAP130 and a 62-kDa
phosphoprotein (7).
SLP-76/ mice have a complete block in thymocyte devel-
opment at the CD4CD8, double-negative stage and lack
peripheral T cells (8, 9). SLP-76 plays an important role in T cell
receptor signal transduction and T cell activation. SLP-76-
deficient Jurkat cells exhibit severely impaired TCRCD3 sig-
naling with deficient PLC-1 activation, calcium mobilization,
ERK phosphorylation, and IL-2 production (10). Overexpres-
sion of SLP-76 in a human T cell line (Jurkat) results in marked
augmentation of TCR mediated activation of nuclear factor of
activated T cells (NFAT) and IL-2 production (2). Single mu-
tation of the three N-terminal domain tyrosine residues (amino
acids 113, 128, and 145), that are phosphorylated after TCR
stimulation, to phenylalanine has no effect on the ability of
SLP-76 to augment the NFAT response. In contrast, double or
triple mutants of these tyrosine residues and deletion mutants of
the NH2-terminal region, the proline-rich Gads binding site, or
the SH2-domain were inactive (11).
The role played by various domains of SLP-76 in T cell
development and function in vivo remains unknown. In this
study, we addressed this issue by reconstituting SLP-76/ mice
with wild-type (WT) SLP-76 and with SLP-76 functional do-
mains deletion mutants.
Materials and Methods
SLP-76 Transgenic Mice. The SLP-76 cDNA mutants 2–156,
224–244, and 421–533 (SH2) were generated using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene).
WT and mutant SLP-76 cDNAs were subcloned in the BamHI
site of the p1017 vector carrying the Lck proximal promoter
(12). NotI linearized DNA was microinjected in fertilized
C57BL6  SJLJ (B6SJL) mouse oocytes. Injected eggs were
implanted into the oviducts of pseudopregnant foster mothers.
Transgenic founder mice, identified by PCR using transgene-
specific primers and confirmed by Southern blotting, were
bred into the SLP-76 deficient (8) background by two rounds
of back-crossing with SLP-76/ mice. Transgenes and the
endogenous SLP-76 locus were determined by PCR. All
animal experiments were performed in compliance with the
National Institutes of Health and institutional guidelines
approved by Children’s Hospital internal animal care and use
committee.
Antibodies and Flow Cytometry Analysis. Streptavidin-FITC,
streptavidin-phycoerythrin (PE), and streptavidin-CyChrome
and mAbs (unlabeled or labeled to FITC or PE) to mouse
antigens were purchased from PharMingen. Cells were stained
and analyzed on a FACSCalibur flow cytometer (Becton Dick-
inson) as described (8). Data on 5–20 105 viable, nonerythroid
cells, as determined by forward versus side scatter, were col-
lected. FACS analysis was performed on cells from at least three
mice aged 6–8 weeks.
Rabbit Anti-SLP-76 Antibodies and Intracellular FACS Analysis. The
IgG fraction of rabbit antiserum against GST-SLP-76 fusion
protein was enriched over a Protein G column and precleared
by GST Sepharose. Thymocytes and splenic T cells were
permeabilized and stained intracellularly, by using CytoPerm
CytoFix Kit (PharMingen), with FITC-conjugated anti SLP-76
antibody.
Western Blot Analysis. Thymocytes (1 106) were lysed in sample
buffer containing SDS and -mercaptoethanol and proteins
were separated on a 10% gel by PAGE, transferred to nitrocel-
lulose membrane, and probed with rabbit anti-SLP-76 antibody,
followed by horseradish peroxidase-conjugated goat anti-rabbit
IgG (Amersham Pharmacia).
Proliferation of Splenic T Cells. Splenocytes were suspended in
RPMI medium 1640 supplemented with L-glutamine, penicillin
Abbreviations: LAT, linker of activated T cells; TCR, T cell antigen receptor; SP, single-
positive; ERK, extracellular signal-regulated protein kinase; WT, wild type; OVA, ovalbu-
min.
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streptomycin, and 10% FBS and cultured in triplicates with
various stimuli. After 72 h, proliferation was assessed by [3H]thy-
midine uptake assay.
Measurement of [Ca2]i. Purified T cells (2  106ml) were
incubated with 4 gml Fluo-4-AM (Molecular Probes) and 10
gml Fura Red (Molecular Probes) in 0.5 ml Tyrode’s buffer
with 0.02% Pluronic F-127 (Sigma) and 1 mM Probenecid
(Sigma). After 45 min at 37°C, cells were preloaded with 2
gml anti-CD3 antibody (Clone KT3, Serotec) on ice for 15
min, kept at room temperature for 30 min to allow cleavage of
the AM esters, washed twice with Tyrode’s buffer, then
stimulated with 5 gml goat F(ab)2 anti-rat IgG (ICN
Cappel) and analyzed by f low cytometry. Intracellular Ca2
concentration is indicated by Fluo-4AMFura Red f luores-
cence intensity ratio.
PLC-1 and ERK Phosphorylation. Purified T cells were left un-
stimulated or were stimulated with 10 gml anti-CD3 (clone
KT3, Serotec) crosslinked with F(ab)2 goat anti-rat IgG for 5
min. For PLC-1, lysates were prepared in 1% Nonidet P-40
lysis buffer supplemented with protease and phosphatase
inhibitors (13), and immunoprecipitated with anti-PLC-1
mAb (Santa Cruz Biotechnology). Precipitated proteins were
resolved by SDS10% PAGE, transferred on nitrocellulose
membrane, and probed with indicated antibodies. For ERK
assay, lysates were prepared in sample buffer containing SDS
and -mercaptoethanol and resolved as above. Activated ERK
was detected using a phospho ERK12-specific mAb followed
by reprobing the membrane with anti-ERK1 mAb (Santa Cruz
Biotechnology).
Hapten-Induced Contact Hypersensitivity. Mice were sensitized by
the application of 100 l of 2% oxazolone (Sigma) in ethanol to
previously shaven abdominal skin. Five days later, 10 l of 1%
oxazolone were applied to the dorsal and ventral surfaces of the
right ear. Ethanol was applied to the left ear. Ear thickness was
measured after 24, 48, and 72 h, using a modified spring-loaded
micrometer (Mitutoyo).
Antibody Responses. Ten- to twelve-week-old mice were immu-
nized intraperitoneally with 100 g of ovalbumin (OVA) pre-
cipitated with alum and bled at day 21. Anti-OVA antibodies
were detected by ELISA as described (14).
Fig. 1. SLP-76 mutants and their expression in thymocytes. (a) WT and SLP-76
deletion mutants used to reconstitute SLP-76/mice. (b) Expression of SLP-76
protein in 1  106 thymocytes assessed by Western blotting using rabbit
anti-SLP-76 antibody. Actin was probed for loading control.
Fig. 2. FACS analysis of thymocytes. Surface expression of (a) CD4 vs. CD8 on total thymocytes. The percentage of cells found in each quadrant is indicated.
(b) TCR on total thymocytes. (c) CD44 and CD25 on DN thymocytes. Cells were triple stained with anti-CD44-FITC, anti-CD25-phycoerythrin, and a mixture of
biotin-conjugated mAbs to CD3, CD4, CD8, B220, Mac1, and Gr-1, followed by streptavidin-CyChrome. Analysis was performed on gated CyChrome negative cells.
Results are representative of three experiments.










Generation of Transgenic Mice. The cDNA constructs used to
generate transgenic mice on SLP-76/ background are shown
in Fig. 1a. Non-transgene-bearing littermates were designated
SLP-76/ and SLP-76/. Transgenic lines that expressed
SLP-76 protein in thymocytes in amounts comparable to those
expressed in SLP-76/ mice, as assessed by Western blotting
(Fig. 1b) and FACS (see Fig. 8, which is published as supporting
information on the PNAS web site, www.pnas.org), were ex-
panded for study. Similar results were obtained when indepen-
dent lines of SLP-76 WT (n 2), SLP-762–156 (n 2), SLP-76
224–244 (n3), and SLP-76 SH2 (n4) mice were examined.
Thymocyte Development. Thymic cellularity in SLP-76/ mice
was 1% that of SLP-76/ mice (1.6  106, n  6). SLP-76/
mice had no detectable CD4CD8 DP, CD4CD8 single-
positive (SP) or CD4CD8 SP thymocytes (Fig. 2a) and no
detectable TCR cells (Fig. 2b). The SLP-76 WT transgene
restored thymic cellularity (112  106, n  4) and thymocyte
development. The percentages of DN, DP, and SP cells and of
TCR cells in SLP-76 WT mice were similar to SLP-76/
littermates (Fig. 2 a and b). SLP-76 2–156 completely failed to
rescue thymocyte cellularity (1.9  106, n  4; Fig. 2 a and b).
SLP-76 224–244 and SLP-76 SH2 restored thymic cellularity
to approximately one third (35 106, n 7) and one half normal
(55 106, n 8), respectively. Progression from DN to DP cells
was partially impaired in SLP-76 224–244 and SLP-76 SH2
mice, as evidenced by an increase in the percentage of DN cells
and a decrease in the percentage of DP cells (Fig. 2a). There was
also a relative increase in the percentage of SP CD8 cells. The
percentage of TCR cells and the density of TCR on thy-
mocytes were decreased compared with SLP-76/ and SLP-76
WT mice (Fig. 2b). In particular, percentages of TCRhi and
TCRintermediate thymocytes were decreased in these mice.
The sequence of development of DN thymocytes is
CD25CD44 3 CD25CD44 3 CD25CD44 3
CD25CD44 cells (15). SLP-76/ mice show a relative in-
crease of the CD25CD44 population, whereas CD25CD44
cells, the most mature among DN T cell progenitors, are almost
undetectable (8). This block was completely overcome by re-
constitution with WT SLP-76 transgene (Fig. 2c). DN cells from
SLP-76 2–156 mice exhibited a block identical to that of
SLP-76/ mice (Fig. 2c). Reconstitution with SLP-76 224–244
and SLP-76 SH2 partially overcame the block in the transition
from the CD25CD44 to the CD25CD44 stage.
Expression of TCR and the CD69 Activation Markers on DP and SP
Thymocytes. Positive selection of thymocytes into SP cells is
accompanied by up-regulation of TCRCD3 and CD69 expres-
sion (16, 17). In both SLP-76/ and SLP-76 WT mice, expres-
sion of TCR and CD69 was up-regulated in SP cells (Fig. 3 and
Fig. 9, which is published as supporting information on the PNAS
web site). Expression of TCR and CD69 was also up-regulated
on SP cells of SLP-76 224–244 and SLP-76 SH2 mice, but the
percentages of TCR and CD69 SP cells and density (MFI)
of TCR and CD69 were lower than in SLP-76/ and SLP-76
WT controls.
Peripheral T Cells. Spleens of SLP-76/ contain no detectable
CD3, CD4, or CD8 cells (Fig. 4a). Introduction of the
SLP-76 WT transgene restored splenic CD3, CD4, and CD8
cells to normal. The SLP-76 2–156 transgene completely failed
Fig. 3. Expression of TCR on DP and SP thymocytes. Gated DP and SP cells
were analyzed for expression of TCR after staining with anti-CD4-
phycoerythrin, anti-CD8-CyChrome, and anti-TCR-FITC. Results are represen-
tative of three experiments.
Fig. 4. FACS analysis and SLP-76 expression in spleen cells. (a) Surface expression of CD3 and of CD4 and CD8 on spleen cells. Results are representative of three
experiments. (b) Expression of SLP-76 protein in purified T cells by intracellular staining with FITC-conjugated rabbit anti-SLP-76 antibody (c) Expression of SLP-76
protein in 1 106 splenocytes assessed by Western blotting.
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to repopulate spleens with T cells. Both SLP-76 224–244 and
SLP-76 SH2 restored splenic CD3 T cells to50% of normal.
In both cases, the density of CD3 expression was about half of
that of SLP-76/ T cells, and there was a relative increase in
CD8 cells (Fig. 4a). Similar phenotypes were obtained with
blood mononuclear cells (data not shown).
Intracellular FACS staining revealed that T cells from spleens
of mice reconstituted with SLP-76 transgenes expressed SLP-76
proteins at comparable intensities (Fig. 4b). Western blotting
revealed that the expressed SLP-76 proteins in splenocytes were
of the expected sizes (Fig. 4c). These results indicate that the lck
proximal promoter is driving sustained SLP-76 expression in
mature T-cells.
T Cell Proliferation and IL-2 Receptor Expression. Splenocytes from
SLP-76 WT mice proliferated normally to anti-CD3. In contrast,
splenocytes from both SLP-76 224–244 and SLP-76 SH2 mice
failed to proliferate to anti-CD3, over a wide range of concen-
trations (0.01 to 10 gml; see Fig. 10, which is published as
supporting information on the PNAS web site). The same T cells
proliferated normally to PMA  ionomycin. Interactions be-
tween IL-2 and IL-2R play an important role in T cell prolifer-
ation and optimal production of IL-2 by T cells, and require
co-stimulation via CD28 (18). IL-2, but not anti-CD28 mAb,
corrected the failure of T cells from SLP-76 224–244 and
SLP-76 SH2 mice to proliferate in response to immobilized
anti-CD3 (Fig. 5). T cells from SLP-76 224–244 and SLP-76
SH2 mice poorly up-regulated IL-2R chain (CD25) expres-
sion following anti-CD3 stimulation (35% and 30% CD25 cells,
respectively) compared with T cells from SLP-76/ mice and
SLP-76 WT mice (93% and 83% CD25 cells, respectively).
CD25 expression on these cells was enhanced by anti-CD28
(54% CD25 cells for SLP-76 224–244 and 43% CD25 cells
for SLP-76 SH2) and IL-2 (59% CD25 cells for SLP-76
224–244 and 52% CD25 cells for SLP-76 SH2) (see Fig. 11,
which is published as supporting information on the PNAS web
site). Similar results were obtained for CD69 expression (data
not shown).
Intracellular Calcium Mobilization, PLC-1, and ERK Phosphorylation.
SLP-76 WT mice mobilized calcium normally following anti-
CD3 ligation. Calcium mobilization was reduced in T cells from
SLP-76 224–244 mice, and minimally affected in T cells from
SLP-76 SH2 mice (Fig. 6a).
Fig. 5. Anti CD3 induced proliferation of splenic T cells. Proliferation of
purified T cells to anti-CD3 (coated at 5 gml) in the presence or absence of
anti-CD28 (coated at 5 gml) and mouse rIL-2 (20 ngml), and to PMA
(50 ngml)  ionomycin (500 M). Results are representative of three
experiments.
Fig. 6. Calcium flux, phosphorylation of PLC-1, and ERK following TCRCD3 ligation in splenic T cells. (a) Ca2 mobilization: T cells preloaded with Fluo-4-AM
and Fura Red were preincubated with anti-CD3 (2gml), washed, then stimulated with 5gml goat F(ab)2 anti-rat IgG (GAR) and analyzed by flow cytometry.
Intracellular Ca2 concentration is indicated by the Fluo-4AMFura Red fluorescence intensity ratio. Io, ionomycin. (b) PLC-1 tyrosine phosphorylation: PLC-1
immunoprecipitates from purified T cells stimulated for 0–5 min with crosslinked anti-CD3 were Western blotted with antiphosphoptyrosine mAb 4G10 (Upper),
and reprobed with anti- PLC-1 (Lower). (c) ERK phosphorylation. Lysates from purified T cells stimulated as above were probed with phospho-ERK-specific
antibody (Upper) and reprobed with ERK-specific antibody (Lower). Results shown are representative of three experiments.









Tyrosine phosphorylation of PLC-1 following TCRCD3
ligation was normal in T cells from WT SLP-76 mice (Fig. 6b),
but was decreased in T cells from SLP-76 224–244 and SLP-76
SH2 mice (Fig. 6b). This decrease was specific, because ty-
rosine phosphorylation of ZAP-70, which is upstream of SLP-76,
was normal in these cells (see Fig. 12, which is published as
supporting information on the PNAS web site).
ERK activation is impaired in SLP-76 deficient Jurkat cells
(10). Phosphorylation of ERK12 following TCRCD3 stimu-
lation in T cells from SLP-76 WT mice was comparable to SLP-
76/ mice. Baseline ERK12 phosphorylation was increased in
T cells from mice reconstituted with mutant transgenes. Induced
ERK12 phosphorylation was4-fold decreased in T cells from
SLP-76 224–244 mice (n 3) and was less sustained (1.5-fold
decreased) in T cells from SLP-76 SH2 (n  3; Fig. 6c).
In Vivo T Cell Effector Responses. Oxazolone sensitized SLP-76/
mice completely failed to exhibit ear swelling up to 72 h after
hapten challenge. Ear swelling in SLP-76 WT mice was similar
to that of SLP 76/ controls. There was partial ear swelling in
both SLP-76 224–244 and SLP-76 SH2 mice (Fig. 7a).
To determine the T helper responses, we measured the
antibody response to OVA. All mice made an IgM antibody
response comparable to that of SLP-76/ mice littermates (Fig.
7b). SLP-76/ and SLP-76 2–156 mice made no IgG1 antibody
or IgE antibody responses to OVA. SLP-76 WT mice made IgG1
and IgE responses comparable to SLP-76/ controls. SLP-76
224–244 made a normal IgG1 response, but had a significantly
decreased IgE response to OVA. SLP-76 SH2 mice made IgG1
and IgE responses to OVA comparable to SLP-76/ controls
(Fig. 7b).
Discussion
The data presented demonstrate that SLP-76 domains play
differential roles in mediating thymopoiesis and activation of
mature T cells in vivo. The failure of the SLP-76 N-terminal
domain mutant to restore thymocyte development in SLP-76/
mice suggests that this domain is critical for signaling by the
preTCR, which is required for the maturation of DN cells and
their transition to DP cells. The block in SLP-76 2–156 mice
could be due to the inability of the SLP-76 mutant to recruit
members of the Vav, Itk andor Nck families, andor additional
proteins that may interact with the SLP-76 N-terminal domain
(2–4). Neither disruption of individual or dual combinations of
the Vav proteins Vav1 and Vav 2 (19–22), nor of the Tec kinases
Itk, Tec, and RlkTxk (23, 24) blocks T cell development at the
DN stage.
SLP-76 224–244, and SLP-76 SH2 behaved similarly in
their ability to reconstitute T cell development and function in
SLP-76/ mice. Both mutants restored DN to DP and DP to SP
transition in the thymus. This restoration was incomplete be-
cause thymic cellularity, CD25CD44mature DN cells, and DP
cells were all decreased (Fig. 2). Furthermore, thymic selection
into SP cells was affected, because these cells had decreased
expression of TCR and of CD69, which are normally up-
regulated upon maturation of DP into SP cells (Fig. 3). These
data suggest that both Gads binding and SH2 domain interac-
tions are necessary for optimal preTCR and TCR signaling in
thymocytes. The skewing of SP thymocytes in these mice toward
CD8 cells is consistent with defective TCR signaling, because
the strength of TCR signaling influences lineage commitment to
CD4 and CD8 with former favored by TCR activation of ERK
kinase (25). Although ERK activation was not measured in
thymocytes, it was decreased in the splenic T cells of these mice.
Mature T cells were present in the blood, spleen, and lymph
nodes of SLP-76 224–244 and SLP-76 SH2 mice and ex-
pressed the SLP-76 transgenes. This finding suggests that the lck
promoter driving the transgene was active in mature T cells, as
has been reported in other studies (26, 27). However, their
percentage was decreased, and they had decreased expression of
TCR and increased proportion of CD8 cells (Fig. 4). T cells
from SLP-76 224–244 and SLP-76 SH2 mice had decreased
CD25 and CD69 expression following ligation of TCRCD3 and
completely failed to proliferate to anti-CD3 (Fig. 5). Up-
regulation of CD25 expression and correction of the proliferative
defect by IL-2 suggest that residual signaling via TCRCD3
occurs in these cells.
Calcium mobilization was decreased in T cells from SLP-76
224–244 mice, but minimally affected in SLP-76 SH2 mice
(Fig. 6a). This finding is consistent with findings in SLP-76
deficient Jurkat T cells transfected with SLP-76 mutants (13).
The decreased response of SLP-76 224–244 mice cannot simply
be explained by lower level of expression of TCRCD3, because
Fig. 7. Hapten Induced Contact Hypersensitivity and antibody response to
OVA. (a) Groups of four mice were sensitized with oxazolone and challenged
with hapten (right ear) or ethanol (left ear). Results represent the difference
in thickness between hapten- and vehicle-challenged ears. (b) Anti-ova IgM,
IgG1, and IgE antibodies in the sera of mice (three mice for SLP-76/ and
SLP-76 2–156, four mice for the others) immunized intraperitoneally with
100 g OVA. Numbers indicates the P values in comparison to SLP-76/ mice
(* indicates P  0.01 by paired t test with Welch’s correction; n.s.  not
significant).
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SLP-76 SH2 mice had a comparable low expression of TCR
CD3, yet fluxed calcium almost normally.
PLC-1 phosphorylation was decreased in T cells from SLP-76
224–244 and SLP-76 SH2 mice (Fig. 6b). Residual PLC-1
phosphorylation in SLP-76 224–244 T cells suggests that
phosphorylation of PLC-1 may occur in the absence of Gads
mediated recruitment of SLP-76 to LAT. This phosphorylation
may involve the recently demonstrated direct interaction of
SLP-76 with PLC-1 (13). Decreased PLC-1 phosphorylation
with almost normal calcium fluxes in SLP-76SH2 mice suggests
that the remaining phosphorylation is sufficient for PLC-1
activation leading to normal calcium flux. A similar finding has
been reported in SLP-76 deficient Jurkat cells reconstituted with
a SLP-76 SH2 domain R448K point mutant (13).
Activation of the MAP kinase ERK was decreased in SLP-76
224–244 mice (Fig. 6c). Decreased generation of DAG subse-
quent to decreased activation of PLC- may have resulted in
impaired activation of the Ras exchange factor RasGRP, and
impaired activation of the RasRafERK pathway (28, 29). Erk
activation was less affected in T cells from SLP-76 SH2 mice,
which mobilized calcium normally. Baseline phosphorylation of
ERK was increased in mutant T cells, particularly in SLP-76
SH2 T cells. It should be noted that deletion of the SH2
domain, in contrast to the R448K mutation that inactivates this
domain, may not only prevent attachment of SLP-76 via SH2 to
target proteins, but may also activate the adapter for signaling
elements which are inhibited by the structure of the intact
protein.
T cells from SLP-76 224–244 and SLP-76 SH2 mice
mounted partial responses to specific antigen. These responses
included partial CHS response to oxazolone, and normal IgG1
antibody response to the TD antigen OVA, with normal IgE
response to OVA in SLP-76 SH2 mice (Fig. 7). CHS involves
the cytokines IFN-, IL-2, IL-4, and IL-10 (30). IgG1 and IgE
responses to TD antigens requires IL-4 and CD40L:CD40 in-
teractions between T and B cells (31). Our findings suggest that
the Gads binding site and the SH2 domain of SLP-76 may be
dispensable, at least partially, for the production of T cell
cytokines involved in these T cell effector responses.
The phenotype of SLP-76 224–244 mice is similar to that of
Gads/ mice, supporting the importance of the SLP-76-Gads-
LAT complex in preTCR and TCR signaling. The defect in
SLP-76 224–244 mice is less severe than that observed in
LAT/ mice (32). This finding suggests that TCR signaling may
proceed, albeit suboptimally, in the absence of SLP-76 recruit-
ment to rafts. This may occur via other LAT-associated proteins,
as suggested by the observation that a LAT mutant that fails to
recruit SLP-76, partially restores T cell signaling in LAT defi-
cient Jurkat cells (33).
T cells from SLP-76 SH2 mice failed to proliferate following
TCR ligation. This finding was unexpected given the ability of
SLP-76 SH2 to restore TCR signaling in SLP-76 deficient
Jurkat T cells. This result suggests that proliferation of primary
T cells has more complex requirements than activation of
biochemical pathways and reporter gene expression in T cell
lines. The SH2 domain of SLP-76 couples the TCR to FYB
SLAP130. FYBSLAP130 has been implicated in actin cytoskel-
etal reorganization (34), which is critical for IL-2 production and
T cell proliferation (35). Molecules other than FYBSLAP130
that interact with the SH2 domain of SLP-76 may also be
important for TCR signaling.
The differential role of SLP-76 domains in T cell development
and function suggests that thymocyte maturation, and activation
of mature T cells is regulated differently. Furthermore, the
results obtained suggest different approaches to selectively in-
terfere with T cell activation in immune-mediated diseases.
We thank Sheryl Freeman for technical assistance. This work was
supported by U.S. Public Health Service Grant AI-35714. V.P. is a
Charles A. King Trust fellow. M.A.F. is supported by a Spanish Ministry
of Science and Technology postdoctoral grant (EX99 12368513).
1. Jackman, J. K., Motto, D. G., Sun, Q., Tanemoto, M., Turck, C. W., Peltz, G. A.,
Koretzky, G. A. & Findell, P. R. (1995) J. Biol. Chem. 270, 7029–7032.
2. Wu, J., Motto, D. G., Koretzky, G. A. & Weiss, A. (1996) Immunity 4, 593–602.
3. Wunderlich, L., Farago, A., Downward, J. & Buday, L. (1999) Eur. J. Immunol.
29, 1068–1075.
4. Bunnell, S. C., Diehn, M., Yaffe, M. B., Findell, P. R., Cantley, L. C. & Berg,
L. J. (2000) J. Biol. Chem. 275, 2219–2230.
5. Liu, S. K., Fang, N., Koretzky, G. A. & McGlade, C. J. (1999) Curr. Biol. 9, 67–75.
6. Ishiai, M., Kurosaki, M., Inabe, K., Chan, A. C., Sugamura, K. & Kurosaki, T.
(2000) J. Exp. Med. 192, 847–856.
7. Motto, D. G., Ross, S. E., Wu, J., Hendricks-Taylor, L. R. & Koretzky, G. A.
(1996) J. Exp. Med. 183, 1937–1943.
8. Pivniouk, V., Tsitsikov, E., Swinton, P., Rathbun, G., Alt, F. W. & Geha, R. S.
(1998) Cell 94, 229–238.
9. Clements, J. L., Yang, B., Ross-Barta, S. E., Eliason, S. L., Hrstka, R. F.,
Williamson, R. A. & Koretzky, G. A. (1998) Science 281, 416–419.
10. Yablonski, D., Kuhne, M. R., Kadlecek, T. & Weiss, A. (1998) Science 281,
413–416.
11. Fang, N., Motto, D. G., Ross, S. E. & Koretzky, G. A. (1996) J. Immunol. 157,
3769–3773.
12. Chaffin, K. E., Beals, C. R., Wilkie, T. M., Forbush, K. A., Simon, M. I. &
Perlmutter, R. M. (1990) EMBO J. 9, 3821–3829.
13. Yablonski, D., Kadlecek, T. & Weiss, A. (2001) Mol. Cell. Biol. 21, 4208–4218.
14. Spergel, J., Mizoguchi, E., Brewer, J., Martin, T., Bhan, A. & Geha, R. (1998)
J. Clin. Invest. 101, 1614–1622.
15. Godfrey, D. I., Kennedy, J., Suda, T. & Zlotnik, A. (1993) J. Immunol. 150,
4244–4253.
16. Swat, W., Dessing, M., von Boehmer, H. & Kisielow, P. (1993) Eur. J. Immunol.
23, 739–746.
17. Bendelac, A., Matzinger, P., Seder, R. A., Paul, W. E. & Schwartz, R. H. (1992)
J. Exp. Med. 175, 731–742.
18. Rudd, C. E. (1996) Immunity 4, 527–534.
19. Zhang, R., Alt, F. W., Davidson, L., Orkin, S. H. & Swat, W. (1995) Nature
(London) 374, 470–473.
20. Tarakhovsky, A., Turner, M., Schaal, S., Mee, P. J., Duddy, L. P., Rajewsky, K.
& Tybulewicz, V. L. J. (1995) Nature (London) 374, 467–470.
21. Tedford, K., Nitschke, L., Girkontaite, I., Charlesworth, A., Chan, G., Sakk, V.,
Barbacid, M. & Fischer, K. D. (2001) Nat. Immunol. 2, 548–555.
22. Doody, G. M., Bell, S. E., Vigorito, E., Clayton, E., McAdam, S., Tooze, R.,
Fernandez, C., Lee, I. J. & Turner, M. (2001) Nat. Immunol. 2, 542–547.
23. Liao, X. C., Littman, D. R. & Weiss, A. (1997) J. Exp. Med. 186, 2069–2073.
24. Rajagopal, K., Sommers, C. L., Decker, D. C., Mitchell, E. O., Korthauer, U.,
Sperling, A. I., Kozak, C. A., Love, P. E. & Bluestone, J. A. (1999) J. Exp. Med.
190, 1657–1668.
25. Bommhardt, U., Basson, M. A., Krummrei, U. & Zamoyska, R. (1999)
J. Immunol. 163, 715–722.
26. Fukuyama, H., Adachi, M., Suematsu, S., Miwa, K., Suda, T., Yoshida, N. &
Nagata, S. (1998) J. Immunol. 160, 3805–3811.
27. Wayne, J., Suh, H., Misulovin, Z., Sokol, K. A., Inaba, K. & Nussenzweig, M. C.
(1994) Immunity 1, 95–107.
28. Ebinu, J. O., Stang, S. L., Teixeira, C., Bottorff, D. A., Hooton, J., Blumberg,
P. M., Barry, M., Bleakley, R. C., Ostergaard, H. L. & Stone, J. C. (2000) Blood
95, 3199–3203.
29. Dower, N. A., Stang, S. L., Bottorff, D. A., Ebinu, J. O., Dickie, P., Ostergaard,
H. L. & Stone, J. C. (2000) Nat. Immunol. 1, 317–321.
30. Kondo, S. & Sauder, D. N. (1995) J. Am. Acad. Dermatol. 33, 786–800.
31. Castigli, E., Alt, F., Davidson, L., Bottaro, A., Mizoguchi, E., Bhan, A. K. &
Geha, R. S. (1994) Proc. Natl. Acad. Sci. USA 91, 12135–12139.
32. Zhang, W., Sommers, C. L., Burshtyn, D. N., Stebbins, C. C., DeJarnette, J. B.,
Trible, R. P., Grinberg, A., Tsay, H. C., Jacobs, H. M., Kessler, C. M., et al.
(1999) Immunity 10, 323–332.
33. Zhang, W., Trible, R. P., Zhu, M., Liu, S. K., McGlade, C. J. & Samelson, L. E.
(2000) J. Biol. Chem. 275, 23355–23361.
34. Krause, M., Sechi, A. S., Konradt, M., Monner, D., Gertler, F. B. & Wehland,
J. (2000) J. Cell Biol. 149, 181–194.
35. Valitutti, S., Dessing, M., Aktories, K., Gallati, H. & Lanzavecchia, A. (1995)
J. Exp. Med. 181, 577–584.
Kumar et al. PNAS  January 22, 2002  vol. 99  no. 2  889
IM
M
U
N
O
LO
G
Y
